Compare Entegris Inc (ENTG) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Revvity Inc — how do they compare? Entegris Inc trades at $161.5 (market cap $22.95B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays the higher dividend (0.27%). Which is the better fit depends on your goals.
| ENTG | RVTY | |
|---|---|---|
Market Cap | $22.95B | $12.91B |
Sector | Technology | Technology |
52-Week High | $184.00 | $117.75 |
52-Week Low | $68.80 | $82.26 |
Enterprise Value | $26.16B | $15.23B |
Dividend Yield | 0.27% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG is trading at $161.18, up 11.77% with strong momentum following three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent Q2 2026 results exceeded expectations with 11% revenue growth and 42% EPS growth driven by AI-related semiconductor demand. Analyst consensus remains strongly positive with 66.7% buy ratings and a $188.67 price target representing 17% upside potential.
The outlook remains favorable given ENTG's positioning in advanced semiconductor materials, with AI-driven demand providing tailwinds. However, elevated valuation multiples (P/E 75.11) and execution risks in capacity expansion warrant monitoring. The company's improving cash flow generation and strong institutional interest support continued growth, though semiconductor cycle sensitivity presents the primary risk to sustained performance.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
